The FDA is extending its review of Johnson & Johnson's Doribax for pneumonia by three months. Regulators say the company has provided new information about the drug that needs to be assessed. Release
The FDA is extending its review of Johnson & Johnson's Doribax for pneumonia by three months. Regulators say the company has provided new information about the drug that needs to be assessed. Release